Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/15071
EVOLUTION OF HTLV-1 PROVIRAL LOAD IN PATIENTS FROM SALVADOR, BRAZIL
Author
Affilliation
Fundação Gonçalo Moniz. Centro de Pesquisas Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil / Escola Baiana de Medicina e Saúde Pública. EBMSP. Salvador, BA, Brasil
Escola Baiana de Medicina e Saúde Pública. EBMSP. Salvador, BA, Brasil
Escola Baiana de Medicina e Saúde Pública. EBMSP. Salvador, BA, Brasil
Fundação Gonçalo Moniz. Centro de Pesquisas Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil / Escola Baiana de Medicina e Saúde Pública. EBMSP. Salvador, BA, Brasil
Fundação Gonçalo Moniz. Centro de Pesquisas Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil / Escola Baiana de Medicina e Saúde Pública. EBMSP. Salvador, BA, Brasil
Escola Baiana de Medicina e Saúde Pública. EBMSP. Salvador, BA, Brasil
Escola Baiana de Medicina e Saúde Pública. EBMSP. Salvador, BA, Brasil
Fundação Gonçalo Moniz. Centro de Pesquisas Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil / Escola Baiana de Medicina e Saúde Pública. EBMSP. Salvador, BA, Brasil
Fundação Gonçalo Moniz. Centro de Pesquisas Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil / Escola Baiana de Medicina e Saúde Pública. EBMSP. Salvador, BA, Brasil
Abstract
Introduction: Variations in human T cell lymphotropic virus type 1 (HTLV-1) proviral load
(PVL) in infected individuals over time are not well understood.
Objective: To evaluate the evolution of proviral load in asymptomatic individuals and
HAM/TSP patients in order to help determine periodicity for measuring proviral load.
Methods: A group of 104 HTLV-1 infected patients, followed at the HTLV reference center
in Salvador, Brazil, were included in the study (70 asymptomatic and 34 HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP) patients). HTLV-1 PVL was measured
using real-time polymerase chain reaction (PCR) at baseline and again at another point,
either ≤ 12 months, between 12-24 months, or ≥ 24 months.
Results: HAM/TSP patients had higher PVL (ranging from 11,041 to 317,009 copies/106 PBMC)
when compared to asymptomatic individuals (ranging from0 to 68,228 copies/106 PBMC). No
statistically significant differenceswere observed in the medians of PVL in HAM/TSP patients
or asymptomatic individuals over time. However, in asymptomatic individuals with a PVL
below50,000 copies/106 PBMC, a statistically significant two-fold increasewas observed over
time.
Conclusion: HTLV-1-PVL remained stable in both asymptomatic individuals and HAM/TSP
patients over time. Frequent monitoring of asymptomatic individuals with low PVLs is recommended
and further studies should be conducted to assess the course of PVL in these
patients over extended periods of time.
Share